Results 131 to 140 of about 8,510 (199)

Infantile Fibrosarcoma of the Hand: Limb-Sparing Treatment With Modern Targeted Oral Chemotherapy and Conservative Surgical Resection. [PDF]

J Hand Surg Glob Online
Vaile JR, Tipps JA, Hurley R, Struble SL, Allen BE, Surrey LF, Finn LS, Balis FM, Laetsch TW, Mendenhall SD.   +9 more
europepmc   +1 more source

First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study.

Journal of Thoracic Oncology
Yi-Long Wu, Hye Ryun Kim, R. Soo, Qing Zhou, H. Akamatsu, G. Chang, Chao-Hua Chiu, H. Hayashi, Sang-We Kim, Y. Goto, T. Kato, Jianying Zhou, V.H.F. Lee, M. Nishio, Baohui Han, Dong-Wan Kim, Shun Lu, A. Polli, J-F. Martini, F. Toffalorio, Chew Hooi Wong, T. Mok   +21 more
semanticscholar   +1 more source

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From <i>ALK</i>-Rearranged NSCLC: Case Report. [PDF]

JTO Clin Res Rep
Wang K, Taslic CA, de Groot P, Parma MA, Paula AG, Caranto M, Shah K, Bose M, Ruoff C, Karacosta LG, Byers LA, Gay CM, Zhang J, Heymach JV, Zhang B.   +14 more
europepmc   +1 more source

Hepatotoxicity of new-generation ALK inhibitors versus crizotinib in patients with non-small cell lung cancer: A systematic review and meta-analysis. [PDF]

iScience
Luo X, Du X, Chen Q, Wang C, Li L, He X, Gong Y, Chen J, Zhong X, Liu Y, Zhang X, Huang L.   +11 more
europepmc   +1 more source

Durable response with mutation-guided <i>ALK</i> inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case report. [PDF]

Rare Tumors
Chaudhry SS, Camidge DR, Clay MR, Wilky BA.   +3 more
europepmc   +1 more source

Immunotherapeutic approaches for ALK-driven Non-Small-Cell Lung Cancer (NSCLC) [PDF]

, 2020
Bussolino, Federico, Chiarle, Roberto, Frutuoso E Ferreira Mota, Ines Sofia   +2 more
core  

Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an <i>ALK+</i> NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib. [PDF]

Lung Cancer (Auckl)
Ou SI, Park CJ, Arter ZL, Nagasaka M.
europepmc   +1 more source

Crizotinib-induced hyperlipidemia in advanced lung adenocarcinoma: A case report and literature review. [PDF]

Medicine (Baltimore)
Ren S, Chen R.
europepmc   +1 more source

Therapeutic Strategies to Overcome ALK Resistance in Cancer [PDF]

, 2021
A. Vv., A, Novello, S.
core  

Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data. [PDF]

Transl Lung Cancer Res
Kim HJ, Lee EA, Park JH, Lee HW.
europepmc   +1 more source